The patient has experienced any grade - gastrointestinal bleeding within  months prior to randomization
No history of gastrointestinal bleeding (GI) bleeding requiring a blood transfusion, endoscopic or operative intervention
Patients must not have had any clinically-significant GI bleeding within  months prior to registration and patients must not have a GI disorder which (at the discretion of the investigator) bears a high risk of perforation or fistula; examples of this include (but are not limited to) Crohns disease or tumor with transmural extension through the gastrointestinal lining
Patients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy
Clinically significant gastrointestinal bleeding within  months prior to the first dose of ALRN-
Patients with any grade - gastrointestinal bleeding within  months prior to enrollment
Active gastrointestinal bleeding
No clinically significant bleeding (i.e. gastrointestinal [GI] bleed, intracranial bleeding) within  months or major surgery within  weeks; minor surgeries (i.e. port placement, cataract surgery) are allowed within  weeks
Any grade - gastrointestinal (GI) bleeding within  months prior to enrollment
Gastrointestinal disease
Active gastrointestinal bleed within  weeks of study enrollment
History of major gastrointestinal bleeding within the last  months or any evidence of active gastrointestinal bleeding excludes the subject.
Active gastrointestinal bleeding within previous  months
Current or recent (within  months) significant gastrointestinal (GI) disease or condition.
History of active gastrointestinal bleeding within  months prior to randomization.
Significant gastrointestinal disease
Patients with inflammatory bowel disease and/or gastrointestinal (GI) ulcers and/or GI fistulas are eligible but only at the discretion of the study PI after personalized review of their medical history and proximity of SBRT targets to gastrointestinal mucosa
Current or recent (within  months) significant gastrointestinal (GI) disease or condition.
Patients with major gastrointestinal bleeding in the prior  months of enrollment.
Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)
Grade  gastrointestinal (GI) bleeding within  months prior to screening
Active gastrointestinal (GI) ulceration or hemorrhage
Patients with any major bleeding current or within the past  weeks. (e.g. recent gastrointestinal [GI] hemorrhage or neurosurgery).
Subjects who within  days prior to randomization have had gastrointestinal or genitourinary bleeding;
Patients with active bleeding are not eligible; specifically, no clinically significant gastrointestinal (GI) bleeding, GI perforation, intra-abdominal abscess or fistula for  months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for  months prior to enrollment
History of gastrointestinal (GI) bleed requiring transfusion
Patients with a history of gastrointestinal bleeding (GIB) within  weeks prior to registration are not eligible
No abnormalities no history of ongoing or recent (less than or equal to  months of registration on protocol therapy) significant gastrointestinal bleeding
Ongoing clinically significant anemia due to factors such as known iron, vitamin B, or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI) bleeding
The patient has significant bleeding disorders, vasculitis, or experienced grade / gastrointestinal (GI) bleeding within  months prior to enrollment
History of clinically significant gastrointestinal bleeding, colitis, or gastrointestinal perforation.
The patient has experienced any grade - gastrointestinal (GI) bleeding within  months prior to enrollment
Patients with active hemoptysis, clinically significant non hemorrhoidal gastrointestinal (GI) bleeding or those with bleeding diathesis
Gastrointestinal (GI) bleed within  days prior to registration on study
Active gastrointestinal bleeding
Active gastrointestinal (GI) hemorrhage within  weeks of study enrollment
Active gastrointestinal (GI) bleed within  weeks of study enrollment
Current or recent (within  months) significant gastrointestinal (GI) disease or condition.
Gastrointestinal bleeding within the past one year
Clinically significant anemia according to investigator's assessment due to factors such as iron, B or folate deficiencies, autoimmune or hereditary hemolysis or gastrointestinal bleeding.
Significant gastrointestinal abnormality.
Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis.
Grade  or higher ongoing gastrointestinal hemorrhage; patients with grade  gastrointestinal bleeding are eligible for participation
No clinically significant gastrointestinal bleeding within  weeks before the first dose of study treatment
Patients who have experienced any grade - gastrointestinal (GI) bleeding within  months prior to first dose of protocol therapy
Clinically significant gastrointestinal bleeding within  months prior to the first dose of ALRN-
Has a clinically significant gastrointestinal (GI) abnormality including:
History of major gastrointestinal bleeding within the last  months. Any evidence of active gastrointestinal bleeding excludes the subject.
Patients must not have clinically significant anemia resulting from iron, B or folate deficiencies, autoimmune or hereditary hemolysis, or gastrointestinal bleeding
Major upper gastrointestinal bleeding episode occurring during the previous year before screening.
Patients at risk of non-AML related major bleeding (e.g. recent gastrointestinal [GI] hemorrhage or neurosurgery).
History of gastrointestinal ulcer or bleeding within  months; any digestive tract dysfunction
Severe gastrointestinal bleeding within  weeks of treatment with G-
History of diverticulitis, rectal bleeding or other lower gastrointestinal (GI) diseases predisposing to GI complications after radiation (will be determined by radiation oncologist)
Significant gastrointestinal bleeding within  weeks prior to consent.
History of clinically-significant cardiovascular disease; gastrointestinal perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within  weeks of first study drug administration
History of major gastrointestinal bleeding within the last  months.
Gastrointestinal (GI) hemorrhage (active or in recent  months)
The patient has significant bleeding disorders or vasculitis; history of significant (in the opinion of the investigator) upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past  years; patients with a history of ulceration, bleeding or perforation in the lower bowel are not excluded
Subjects must not have clinically significant bleeding (i.e. gastrointestinal [GI] bleed, intracranial bleeding) within  months or have had major surgery within  weeks; minor surgeries (i.e. port placement, cataract surgery) are allowed if completed more than  weeks from the start of treatment
Have a history of or active significant gastrointestinal (GI) bleeding within  months of the first dose of brigatinib.
No patients with clinically significant gastrointestinal (GI) bleeding or bleeding diathesis within  days prior to registration
History of clinically significant gastrointestinal (GI) bleeding within prior  months prior to enrollment
Clinical significant gastrointestinal bleeding in the  months prior to Cycle  Day  (CD) first dose
History of diverticulitis, rectal bleeding or other lower gastrointestinal (GI) diseases predisposing to GI complications after radiation (will be determined by radiation oncologist)
History of severe gastrointestinal bleeding within  months; patients with gastrointestinal blood loss due to KS may be included
History of gastrointestinal disease
Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within  months prior to the planned first dose of study drug.
Patients with poorly controlled bleeding from gastric antral vascular ectasia (GAVE) or other gastrointestinal (GI) sites
Subject has active gastrointestinal ulcer or gastrointestinal bleeding within  months prior to the planned first dose of study drug.
No history of major bleeding, recent or active myocardial ischemia, gastrointestinal (GI) perforation, cerebrovascular accidents or other significant illness
Subject has a history of gastrointestinal bleeding within  days prior to the first dose of study drug.
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding
Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding.
History of active peptic ulcer disease or major upper gastrointestinal (GI) bleed <  months; history of GI bleeding from the colorectal cancer primary is not an exclusion criterion
Current (significant or uncontrolled) gastrointestinal bleeding
Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within  months prior to receiving study drugs.
History of gastrointestinal bleeding within the past  months
Gastrointestinal Function
Patients with acute gastrointestinal bleeding within  month of study entry
Known active gastrointestinal (GI) bleeding.
Clinically significant gastrointestinal (GI) bleeding within  months prior to Cycle , Day 
Clinically significant gastrointestinal bleeding occurring <=  weeks prior to randomization
Clinically significant gastrointestinal abnormalities, apart from gastric cancer, including uncontrolled inflammatory gastrointestinal diseases
Active gastrointestinal bleeding
No gastrointestinal bleeding within  year of study entry.
History of gastrointestinal (GI) hemorrhage
Clinically significant gastrointestinal (GI) abnormalities that may increase the risk for GI bleeding.
Experienced any serious Grade - gastrointestinal bleeding within  months prior to study entry
Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within  months prior to the first dose of study drug.
No history of gastrointestinal obstruction, or conditions that increase the risk of gastrointestinal obstruction, perforation, bleeding or impairment of the gastrointestinal wall; no abdominal surgery within  days of registration
Evidence of >= grade  gastrointestinal toxicity (including, but not limited to: nausea, vomiting, anorexia, gastrointestinal pain)
Recent or ongoing clinically significant gastrointestinal disorder (e.g., malabsorption, bleeding, inflammation, emesis, diarrhea > grade )
Gastrointestinal bleeding; note that the presence of any symptoms (dyspnea, fatigue, angina, weakness, malaise, melena, hematochezia, hematemesis, anemia, abdominal pain) will require clinical assessment to rule out gastrointestinal bleeding
Participant has an underlying predisposition to gastrointestinal (GI) or rectal bleeding are considered ineligible for study participation
Individuals with any history of transfusion-dependent gastrointestinal bleeding, gastrointestinal perforation or gastrointestinal obstruction; if any of these events had been due to a malignancy of the GI tract and the malignancy has since been removed, the patient is eligible
Patients with a diverting ileostomy, with a history of inflammatory bowel disease, familial adenomatous polyposis (FAP), or active gastrointestinal (GI) symptoms (gastrointestinal bleed, diarrhea, severe abdominal pain, etc.)
Acute gastrointestinal (GI) bleeding
Patients who had prior major gastrointestinal surgery removing part of gastrointestinal tract and/or gall bladder.
Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis (Parts D and E only).
